Observation on the efficacy of liposomal doxorubicin intensive preconditioning regimen and allogeneic hematopoietic stem cell transplantation for treatment of leukemia
10.3760/cma.j.cn115356-20201120-00281
- VernacularTitle:脂质体多柔比星强化预处理方案异基因造血干细胞移植治疗白血病的效果观察
- Author:
Xiaohan ZHANG
1
;
Xin DU
;
Yun CAI
;
Pengcheng WANG
;
Changru LUO
;
Xiaoqing LI
Author Information
1. 深圳市第二人民医院血液内科，深圳 518035
- Keywords:
Leukemia;
Hematopoietic stem cell transplantation;
Transplantation preconditioning;
Doxorubicin
- From:
Journal of Leukemia & Lymphoma
2022;31(2):96-98
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of liposomal doxorubicin intensive preconditioning regimen and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treatment of leukemia.Methods:The data of 20 patients with intensive preconditioning regimen allo-HSCT who were admitted to Shenzhen Second People's Hospital from January 2016 to June 2017 were retrospectively analyzed. The transplantation effect, occurrence of complications and prognosis of patients were analyzed.Results:The median time of granulocyte engraftment was 17 d (13-23 d); the median time of platelet engraftment was 22.5 d (minimum 13 d, maximum >90 d). The acute graft-versus-host disease (GVHD) and chronic GVHD occurred in 2 cases and 1 case, respectively. Eight cases occurred hemorrhagic cystitis, 15 cases occurred Epstein-Barr viremia, 8 cases occurred cytomegaloviremia, 1 case occurred sepsis, 1 case occurred acute liver injury, and 2 cases occurred fungal pneumonia. The median follow-up time was 31.7 months (0.8-53.8 months). One patient died of intracranial infection on the 25th day after transplantation; 3 patients relapsed during the follow-up period, and 2 of them died; the other 16 patients carried 100% donor genes during the follow-up period.Conclusions:The liposomal doxorubicin intensive preconditioning regimen and allo-HSCT have a good effect on leukemia. Increasing the intensity of pretreatment does not increase the treatment-related adverse reactions. The incidence rates of Epstein-Barr viremia and cytomegaloviremia are high, but they are improved after active treatment.
